دورية أكاديمية
[Characteristics of purchases of hypoglycemic agents in pharmacy retail sector in 2016-2020 years dynamics].
| العنوان: | [Characteristics of purchases of hypoglycemic agents in pharmacy retail sector in 2016-2020 years dynamics]. |
|---|---|
| المؤلفون: | Kurkin DV; Moscow State University of Medicine and Dentistry of A.I. Evdokimov., Makarova EV; Moscow State University of Medicine and Dentistry of A.I. Evdokimov; N.A. Semashko National Research Institute of Public Health., Krysanov IS; Moscow State University of Medicine and Dentistry of A.I. Evdokimov; Moscow State University of Food Production., Bakulin DA; Volgograd State Medical University., Robertus AI; Moscow State University of Medicine and Dentistry of A.I. Evdokimov; Pirogov Russian National Research Medical University., Ivanova OV; Moscow State University of Medicine and Dentistry of A.I. Evdokimov., Kolosov YA; Moscow State University of Medicine and Dentistry of A.I. Evdokimov., Kudrin RA; Volgograd State Medical University. |
| المصدر: | Problemy endokrinologii [Probl Endokrinol (Mosk)] 2023 Aug 30; Vol. 69 (4), pp. 50-60. Date of Electronic Publication: 2023 Aug 30. |
| نوع المنشور: | English Abstract; Journal Article |
| اللغة: | Russian |
| بيانات الدورية: | Publisher: Media Sfera Country of Publication: Russia (Federation) NLM ID: 0140673 Publication Model: Electronic Cited Medium: Internet ISSN: 2308-1430 (Electronic) Linking ISSN: 03759660 NLM ISO Abbreviation: Probl Endokrinol (Mosk) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2015-> : Moskva : Media Sfera Original Publication: Moskva, Medit︠s︡ina. |
| مواضيع طبية MeSH: | Pharmacies* , Gliclazide* , Pharmacy* , Metformin*/therapeutic use, Humans ; Hypoglycemic Agents/therapeutic use ; Glyburide ; Dipeptidyl Peptidase 4 |
| مستخلص: | Background: Procurement of medicines reflects the demand and frequency of prescribing certain drugs, which makes it possible to assess the quality of medical care and compliance with standards. The Russian pharmaceutical market is dynamically developing and expanding, therefore, the commercial sector of drug circulation is a significant part of it and should be studied along with public procurement. Given the significant number of patients diagnosed with diabetes mellitus (DM) in our country, we considered it appropriate and interesting to analyze the structure and volume of turnover of antidiabetic drugs in the retail trade over five years. Aim: to assess the dynamics of the cost and sales volumes of hypoglycemic drugs in the commercial sector for 2019-2020 compared to 2016. Materials and Methods: The analysis was made on the basis of the data of antidiabetic drugs purchases in Russian pharmacies in 2016 and 2019-2020, according to 95257 pharmacies data. Results: In 2020, compared to 2016, we see a significant increase in the number of packages purchases (+14,952,897 rub.) and the purchases total amount (+9,377,975,722 rub.), in parallel with the increase in average price per box of the hypoglycemic drug +199, 57 rub. The average price for DPP4 decreased. The cost per pack of metformin remains one of the lowest, second only to glibenclamide and gliclazide. The most expensive drugs include GLP1 group representatives. Insulin purchases have halved, when budget for GLP1 have increased by 10 times, for SGLT2 by 9.5 times, and for DPP4 by 2.1 times. In 2020, metformin gliclazide, a combination of glibencladimide with metformin, glibenclamide and vildgaliptin remain leaders in the number of purchased packages. The purchase leaders in terms of budget share are: metformin, gliclazide, liraglutide, vildagliptin and dapagliflozinCONCLUSION: There are positive trends in the demand for more effective innovative hypoglycemic drugs, however, the affordability of drugs still dominates over the feasibility of their clinical use, and a high percentage of drug turnover in the commercial sector might indicates insufficient funding for drug provision for patients with diabetes mellitus. |
| References: | Diabetes Metab. 2017 Feb;43(1):48-58. (PMID: 27745828) BMC Endocr Disord. 2022 Oct 19;22(1):251. (PMID: 36261824) Ther Adv Endocrinol Metab. 2021 Mar 9;12:2042018821997320. (PMID: 33767808) Diabetologia. 2022 Oct;65(10):1575-1586. (PMID: 35902386) Sci Rep. 2016 Sep 07;6:32714. (PMID: 27600499) Diabetes Care. 2022 Jan 1;45(Suppl 1):S4-S7. (PMID: 34964881) Curr Opin Nephrol Hypertens. 2022 Sep 1;31(5):456-463. (PMID: 35894280) BMJ. 2021 May 11;373:n1091. (PMID: 33975892) Front Immunol. 2015 Jul 27;6:386. (PMID: 26284071) |
| المشرفين على المادة: | 0 (Hypoglycemic Agents) G4PX8C4HKV (Gliclazide) SX6K58TVWC (Glyburide) EC 3.4.14.5 (Dipeptidyl Peptidase 4) 9100L32L2N (Metformin) |
| تواريخ الأحداث: | Date Created: 20230911 Date Completed: 20230912 Latest Revision: 20231003 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10520906 |
| DOI: | 10.14341/probl13200 |
| PMID: | 37694867 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2308-1430 |
|---|---|
| DOI: | 10.14341/probl13200 |